Feed Top Reports Pricing

⌘K

00:15:14·141d

SECFiling

SEC Form EFFECT filed by Entrada Therapeutics Inc.

TRDA· Entrada Therapeutics Inc.

Health Care

Original source

Companies

TRDA
Entrada Therapeutics Inc.
Health Care

Recent analyst ratings

Apr 1UpdateCantor Fitzgerald-
Feb 11UpdateGuggenheim$20.00
Jan 28UpdateOppenheimer$21.00
Dec 6UpdateROTH MKM$29.00
Jan 5UpdateOppenheimer$22.00
Apr 3UpdateH.C. Wainwright$25.00

Related

INSIDER21d
SEC Form 4 filed by Wentworth Kory James
ANALYST22d
Cantor Fitzgerald initiated coverage on Entrada Therapeutics
INSIDER43d
SEC Form 4 filed by Entrada Therapeutics Inc.
INSIDER43d
SEC Form 4 filed by Entrada Therapeutics Inc.
INSIDER48d
Chief Financial Officer Wentworth Kory James sold $97,892 worth of shares (7,988 units at $12.25), decreasing direct ownership by 5% to 137,987 units (SEC Form 4)
INSIDER51d
CEO Doshi Dipal was granted 139,400 shares and covered exercise/tax liability with 29,050 shares, increasing direct ownership by 27% to 526,014 units (SEC Form 4)
INSIDER51d
Chief Financial Officer Wentworth Kory James was granted 44,600 shares and covered exercise/tax liability with 8,651 shares, increasing direct ownership by 33% to 145,975 units (SEC Form 4)
INSIDER51d
President & COO Dowden Nathan J was granted 55,800 shares and covered exercise/tax liability with 21,261 shares, increasing direct ownership by 19% to 213,598 units (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022